Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 1, 2008, Pages 35-43

  Currier, Judith ^a   Scherzer, Rebecca ^b   Bacchetti, Peter ^c   Heymsfield, Steven ^d   Lee, Daniel ^e   Sidney, Stephen ^f   Tien, Phyllis C ^b,c,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f DIVISION OF RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyslipidemia; Fat distribution; HIV infection; Lipid levels; Lipodystrophy; Women

Indexed keywords

ANTILIPEMIC AGENT; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS FAT; VIRUS LOAD;

ADIPOSE TISSUE; ADULT; FEMALE; HIV INFECTIONS; HUMANS; LIPID METABOLISM; LIPOPROTEINS; MULTIVARIATE ANALYSIS; TRIGLYCERIDES;

EID: 42649088058     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318164227f     Document Type: Article

References (37)

1. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991;3:143-158.
2. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
3. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
4. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24:416-420.
5. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
6. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
7. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
8. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-188.
9. Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection. 1999;27:77-81.
10. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2001;26:443-448.
11. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107-113.
12. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr. 2003;34:58-61.
13. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
14. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
15. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
16. FRAM Study Investigators. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-571.
17. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131.
18. Palella FJ Jr, Cole SR, Chmiel JS, et al. Anthropometrics and examiner-reported body habitus abnormalities in the Multicenter AIDS Cohort Study. Clin Infect Dis. 2004;38:903-907.
19. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2003;34:461-466.
20. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897-1904.
21. Tien PC, Benson C, Zolopa AR, et al. The study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006;163:860-869.
22. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41:1105-1116.
23. Hughes GH, Cutter G, Donahue R, et al. Recruitment in the Coronary Artery Disease Risk Development in Young Adults (CARDIA) study. Control Clin Trials. 1987;8(4 Suppl):68S-73S.
24. Hill JO, Sidney S, Lewis CE, et al. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr. 1999;69:381-387.
25. Hoegerman GS, Lewis CE, Flack J, et al. Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) study. J Am Coll Cardiol. 1995;25:895-900.
26. Sidney S, Jacobs DR Jr, Haskell WL, et al. Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol. 1991;133:1231-1245.
27. Gallagher D, Belmonte D, Deurenberg P, et al. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol. 1998;275:E249-E258.
28. Shen W, Wang Z, Tang H, et al. Volume estimates by imaging methods: model comparisons with visible woman as the reference. Obes Res. 2003;11:217-225.
29. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44-54.
30. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
31. Garg A. Lipodystrophies. Am J Med. 2000;108:143-152.
32. Snijder MB, Visser M, Dekker JM, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia. 2005;48:301-308.
33. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
34. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
35. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649.
36. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother. 2001;45:30-37.
37. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.